drugset / Trial / NCT00291577
Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
Timeline
- Start
- 2006-07
- Primary completion
- 2008-10
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 37.5 mg | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |